The Cigna Group (CI)

Cigna trades at a significant discount to intrinsic value — a forward P/E of 8.4x and PEG of 0.85 suggest the market is underpricing its steady earnings and revenue growth profile anchored by its Evernorth pharmacy benefit management and commercial health plan businesses. With 24 analysts covering the stock, a 79% Buy rate, and a consensus target implying ~21% upside, institutional conviction is high. The primary risk is margin pressure from elevated medical cost trends and ongoing uncertainty in managed care reimbursement policy.

• Q2/Q3 2025 earnings reports — further EPS beats could narrow the ~$59 gap between current price and the $341 consensus target and drive upward estimate revisions
• Continued growth of the Evernorth segment, particularly Accredo specialty pharmacy and Express Scripts PBM, which are high-margin and contract-renewal driven
• Potential capital return acceleration via share buybacks, given the low forward P/E and strong free cash flow generation typical of managed care operators

• Medical Loss Ratio (MLR) expansion — if healthcare utilization surges above expectations, margins could compress materially, as seen across the managed care sector in recent quarters
• Federal or state regulatory action targeting pharmacy benefit managers (PBMs) could structurally impair Evernorth's revenue model, which represents a significant share of Cigna's earnings
• Macroeconomic-driven membership attrition — an employment slowdown could reduce commercial health plan enrollment, directly pressuring premium revenue and per-member profitability

Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.

Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →